Contrasting Oramed Pharmaceuticals (NASDAQ:ORMP) and Evolus (NASDAQ:EOLS)

Oramed Pharmaceuticals (NASDAQ:ORMP) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Profitability

This table compares Oramed Pharmaceuticals and Evolus’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	-6.83%	-6.25%
Evolus	-17.38%	N/A	-21.57%

Valuation & Earnings

This table compares Oramed Pharmaceuticals and Evolus”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	$2.00 million	71.39	$64.05 million	$1.49	2.37
Evolus	$297.18 million	0.93	-$51.64 million	($0.81)	-5.27

Oramed Pharmaceuticals has higher earnings, but lower revenue than Evolus. Evolus is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Oramed Pharmaceuticals has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, Evolus has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Oramed Pharmaceuticals and Evolus, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0	1	0	0	2.00
Evolus	1	1	4	0	2.50

Evolus has a consensus price target of $16.00, suggesting a potential upside of 274.71%. Given Evolus’ stronger consensus rating and higher probable upside, analysts clearly believe Evolus is more favorable than Oramed Pharmaceuticals.

Insider and Institutional Ownership

12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. Comparatively, 90.7% of Evolus shares are owned by institutional investors. 17.8% of Oramed Pharmaceuticals shares are owned by insiders. Comparatively, 6.1% of Evolus shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Oramed Pharmaceuticals beats Evolus on 8 of the 14 factors compared between the two stocks.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

About Evolus

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.